Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
-
Randomized Controlled Trial Comparative Study Clinical Trial
Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
Radiation therapy is often the primary treatment for advanced cases of head and neck cancers not considered suitable for radical surgery. In these cases locoregional tumour control rates are low and has warranted innovative treatment modifications, such as altered fractionation schedules and combination with chemotherapy. ⋯ Following shortening overall treatment time from 7 weeks to 17 consecutive days and dose of radiotherapy from 70 to 55.3 Gy the results in the radiotherapy only treated patients are identical. A significant improvement regarding local tumour control and survival was seen following administration of MMC to the accelerated fractionated treatment.